McKesson Corporation (NYSE:MCK) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 23.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 177,669 shares of the company's stock after selling 53,789 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.14% of McKesson worth $119,569,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Sequoia Financial Advisors LLC grew its stake in shares of McKesson by 24.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 8,696 shares of the company's stock worth $5,852,000 after purchasing an additional 1,688 shares during the period. Value Partners Investments Inc. lifted its stake in shares of McKesson by 11.0% in the 1st quarter. Value Partners Investments Inc. now owns 4,305 shares of the company's stock valued at $2,899,000 after purchasing an additional 425 shares during the period. Pure Financial Advisors LLC boosted its holdings in McKesson by 27.5% during the first quarter. Pure Financial Advisors LLC now owns 1,010 shares of the company's stock worth $680,000 after buying an additional 218 shares in the last quarter. Tyche Wealth Partners LLC purchased a new stake in McKesson during the first quarter worth $205,000. Finally, Alpine Bank Wealth Management acquired a new stake in McKesson during the first quarter valued at $114,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Stock Down 0.2%

Shares of MCK opened at $719.18 on Thursday. McKesson Corporation has a 52-week low of $464.42 and a 52-week high of $733.10. The stock has a market cap of $89.98 billion, a PE ratio of 27.84, a price-to-earnings-growth ratio of 1.44 and a beta of 0.49. The firm's fifty day moving average is $710.10 and its two-hundred day moving average is $650.18.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $10.12 earnings per share for the quarter, topping analysts' consensus estimates of $9.83 by $0.29. The firm had revenue of $90.82 billion for the quarter, compared to analyst estimates of $94 billion. McKesson had a net margin of 0.92% and a negative return on equity of 201.12%. McKesson's quarterly revenue was up 18.9% on a year-over-year basis. During the same period in the previous year, the business posted $6.18 earnings per share. As a group, research analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Stockholders of record on Monday, June 2nd will be given a $0.71 dividend. The ex-dividend date is Monday, June 2nd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.39%. McKesson's dividend payout ratio (DPR) is presently 10.99%.

Insider Activity

In other McKesson news, EVP Thomas L. Rodgers sold 510 shares of the company's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $717.91, for a total value of $366,134.10. Following the completion of the sale, the executive vice president now directly owns 5,435 shares in the company, valued at $3,901,840.85. This represents a 8.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 543 shares of the firm's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $726.51, for a total value of $394,494.93. Following the completion of the sale, the chief accounting officer now directly owns 1,972 shares of the company's stock, valued at $1,432,677.72. This trade represents a 21.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,117 shares of company stock worth $23,526,451 over the last ninety days. Corporate insiders own 0.11% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MCK. Cfra Research downgraded shares of McKesson from a "moderate buy" rating to a "hold" rating in a research report on Friday, April 4th. Wells Fargo & Company set a $766.00 price target on McKesson and gave the stock an "equal weight" rating in a report on Tuesday, June 3rd. UBS Group raised their price objective on McKesson from $708.00 to $805.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Bank of America boosted their price objective on McKesson from $755.00 to $800.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Finally, Mizuho increased their target price on McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a research report on Thursday, April 3rd. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $696.42.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.